Breaking News

Biogen Appoints EVP, CCO

March 30, 2016

Merck veteran to lead commercial strategy

Michel Vounatsos has been appointed executive vice president and chief commercial officer at Biogen, effective April 18, 2016.
 
Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the company’s product portfolio and the development of the commercial infrastructure to support key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the management team.
 
Mr. Vounatsos joins the company from Merck, where he spent 20 years, most recently as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China.
 
“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks